Prognostic and Predictive Biomarkers in Early Stage NSCLC
Currently, tumor stage remains the strongest predictor of survival in NSCLC. Early-stage patients are treated primarily by surgical resection. However, 30% to 55% of these patients develop recurrence and die of their disease. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in individual patients. For this reason there is an urgent need to search for new individual biomarkers and gene signatures in the tumor tissue. Many studies have investigated several molecular alterations in early lung cancer and their predictive and prognostic implications are still a matter of clinical research and even for the most promising are not yet ready for prime time application. Currently, randomized clinical trials are exploring the real value of these new diagnostic tools.
Conclusions
Currently, tumor stage remains the strongest predictor of survival in NSCLC. Early-stage patients are treated primarily by surgical resection. However, 30% to 55% of these patients develop recurrence and die of their disease. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in individual patients. For this reason there is an urgent need to search for new individual biomarkers and gene signatures in the tumor tissue. Many studies have investigated several molecular alterations in early lung cancer and their predictive and prognostic implications are still a matter of clinical research and even for the most promising are not yet ready for prime time application. Currently, randomized clinical trials are exploring the real value of these new diagnostic tools.
SHARE
![Pediatric Supportive Care (PDQ®): Supportive care - Patient Information [NCI]-Overview](https://cdnus.oss-us-west-1.aliyuncs.com/libs/images/NewsJpg/cate_6/072_215x160.jpg)
